|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
IL124015A0
(en)
*
|
1998-04-08 |
1999-01-26 |
Yeda Res & Dev |
Pharmaceutical compositions comprising a protein
|
|
FR2786104B1
(fr)
*
|
1998-11-25 |
2002-12-27 |
Centre Nat Rech Scient |
Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
|
|
AU784550B2
(en)
*
|
1999-04-13 |
2006-05-04 |
Kenneth S. Warren Institute, Inc., The |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
US7410941B1
(en)
|
1999-04-13 |
2008-08-12 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
|
|
US6171620B1
(en)
|
1999-04-27 |
2001-01-09 |
Health Research, Inc. |
Method of enhancing the efficacy of anti-tumor agents
|
|
US6747002B2
(en)
*
|
1999-05-11 |
2004-06-08 |
Ortho-Mcneil Pharmaceutical, Inc. |
Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
|
|
US20030152562A1
(en)
*
|
2001-10-23 |
2003-08-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Vitro micro-organs, and uses related thereto
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
EP2206720A1
(en)
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2001254625B2
(en)
*
|
2000-05-02 |
2006-02-02 |
Action Pharma A/S |
Use of alpha-MSH and EPO for preventing or treating ischemic conditions
|
|
US20020061849A1
(en)
*
|
2000-05-02 |
2002-05-23 |
Soren Nielsen |
Methods for treatment of diseases associated with inflammation under non-ischemic conditions
|
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
|
US20020169128A1
(en)
*
|
2001-04-09 |
2002-11-14 |
Geroge Sigounas |
Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
|
|
EP1930023A3
(en)
*
|
2001-04-09 |
2008-08-06 |
East Carolina University |
Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
|
|
WO2002097038A2
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
|
EP1459762B1
(en)
*
|
2001-11-02 |
2008-07-02 |
Yoshiko Yasuda |
Use of emp9 for the prevention of proliferative organ diseases
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
GB0211578D0
(en)
*
|
2002-05-21 |
2002-06-26 |
Univ Belfast |
Medicaments
|
|
DE10234192B4
(de)
*
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
BRPI0414887A
(pt)
*
|
2003-09-29 |
2006-12-12 |
Warren Pharmaceuticals Inc E T |
métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
|
|
EP1686979A4
(en)
*
|
2003-11-07 |
2010-03-03 |
Jackson H M Found Military Med |
ACTIVATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION
|
|
DE102004063927A1
(de)
*
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
|
WO2005099773A1
(en)
*
|
2004-04-05 |
2005-10-27 |
University Of Vermont And State Agricultural College |
Use of erythropoietin for treatment of cancer
|
|
US20110076255A1
(en)
*
|
2005-11-07 |
2011-03-31 |
Pecora Andrew L |
Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
|
|
US20080249001A1
(en)
*
|
2006-10-25 |
2008-10-09 |
Ajinomoto Co. Inc. |
Agents that alleviate side-effects caused by chemotherapy agents
|
|
RU2426174C1
(ru)
*
|
2010-03-29 |
2011-08-10 |
Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" |
Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
|
|
US9533010B2
(en)
*
|
2011-10-31 |
2017-01-03 |
Amorcyte, Llc |
Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
|
|
PT2970493T
(pt)
|
2013-03-15 |
2019-06-27 |
Univ Leland Stanford Junior |
Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
|
|
EP4340865A4
(en)
*
|
2021-05-18 |
2025-04-02 |
Attias, Eyal |
USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION
|